Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
37724
CAS Number:
73963-72-1
Cilostazol
Purity:
≥ 99% (ensayo)
Synonym(s):
6-[4-(1-Ciclohexil- 1H- tetrazol-5-il)butoxi]-3,4-dihidro-2(1H)-quinolinona
Documents
$18.50 /1G
Tamaño
Request Bulk Quote
Información del producto

Cilostazol is a potent phosphodiesterase III inhibitor, primarily utilized in the management of intermittent claudication, a condition characterized by muscle pain due to inadequate blood flow. This compound enhances blood flow by inhibiting platelet aggregation and promoting vasodilation, making it a valuable therapeutic agent in cardiovascular health. Cilostazol's unique mechanism of action not only alleviates symptoms associated with claudication but also improves walking distance and overall quality of life for patients.

In addition to its primary use in treating peripheral vascular disease, Cilostazol is being explored for its potential benefits in other areas, such as stroke prevention and improving outcomes in patients with coronary artery disease. Its favorable safety profile and effectiveness make it a preferred choice among healthcare professionals. Researchers and industry professionals can leverage Cilostazol's properties for innovative applications in drug development and clinical research, contributing to advancements in cardiovascular therapies.

Número CAS
73963-72-1
Fórmula molecular
C20H27N5O2
Peso molecular
369.47
Número MDL
MFCD00866780
Punto de fusión
158 - 162 °C
Condiciones
Conservar entre 2 y 8 °C.
Información general
Número CAS
73963-72-1
Fórmula molecular
C20H27N5O2
Peso molecular
369.47
Número MDL
MFCD00866780
Punto de fusión
158 - 162 °C
Condiciones
Conservar entre 2 y 8 °C.
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Cilostazol is widely utilized in research focused on:

  • Cardiovascular Health: Primarily used to treat intermittent claudication, cilostazol improves blood flow and reduces pain during physical activity, making it essential for patients with peripheral artery disease.
  • Anti-platelet Activity: Its ability to inhibit platelet aggregation makes cilostazol valuable in preventing thrombotic events, particularly in patients at risk for stroke or heart attack.
  • Research on Metabolic Disorders: Studies indicate cilostazol may have beneficial effects on insulin sensitivity and lipid profiles, making it a candidate for research in diabetes and metabolic syndrome.
  • Neuroprotective Effects: Emerging research suggests cilostazol may offer neuroprotective benefits, potentially aiding in the treatment of neurodegenerative diseases such as Alzheimer’s.
  • Combination Therapies: Cilostazol is often explored in combination with other medications to enhance therapeutic outcomes, particularly in cardiovascular and metabolic health, providing a synergistic effect that can improve patient care.

Citas